Results 231 to 240 of about 113,185 (266)
Some of the next articles are maybe not open access.
JAMA
ImportanceChronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100 000 people and is newly diagnosed in approximately 9300 individuals per year in the US. Approximately 150 000 people in the US and 5 million worldwide have CML.ObservationsChronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the ...
Elias, Jabbour, Hagop, Kantarjian
openaire +2 more sources
ImportanceChronic myeloid leukemia (CML) has an annual incidence of 2 cases per 100 000 people and is newly diagnosed in approximately 9300 individuals per year in the US. Approximately 150 000 people in the US and 5 million worldwide have CML.ObservationsChronic myeloid leukemia is a myeloproliferative neoplasm characterized by the presence of the ...
Elias, Jabbour, Hagop, Kantarjian
openaire +2 more sources
Allografting for chronic myeloid leukemia
Current Opinion in Hematology, 1997Allogeneic stem cell transplantation is the only curative therapy for chronic myeloid leukemia. There have been several recent advances in this field. Early data suggest that blood-derived stem cells are an effective substitute for bone marrow. Allografting can be performed using progenitor cells from other family members, unrelated donors, and ...
D G, Savage, J M, Goldman
openaire +2 more sources
Splenectomy in Chronic Myeloid Leukemia
Annals of Internal Medicine, 1978We review splenectomy in chronic myeloid leukemia, emphasizing recent studies that have evaluated early splenectomy during the chronic phase of the disease. Despite current interest in splenectomy in chronic myeloid leukemia, uncontrolled clinical trials to date suggest that the operation during the early phase neither delays the onset of blastic ...
D J, Wolf, R T, Silver, M, Coleman
openaire +2 more sources
Treatment of Chronic Myeloid Leukemia
Annual Review of Medicine, 1980Most known chemotherapy agents, used singly, may induce remission of CML. Those that best alleviate symptoms (anemia, splenomegaly, etc) do not change either the Ph' chromosome anomaly in the hemopoietic cells nor the median delay of 3--4 years before fatal blastic transformation.
openaire +2 more sources
Immunotherapy of Chronic Myeloid Leukemia
2006Imatinib has become standard therapy for all phases of chronic myeloid leukemia (CML). However, data generated by monitoring several thousands of patients worldwide suggest that although imatinib is highly active against the differentiated mass of CML cells, it probably fails to eradicate all residual leukemia cells, even in the best responders.
BOCCHIA M., LAURIA F.
openaire +3 more sources
Ponatinib for Chronic Myeloid Leukemia
New England Journal of Medicine, 2012The treatment of patients with chronic myeloid leukemia (CML) must be ranked as one of the great medical success stories of the past 30 years. The demonstration that the Philadelphia (Ph) chromosome carries a fusion gene formed by the juxtaposition of BCR and ABL genetic sequences focused attention on the possibility that the tyrosine kinase activity ...
openaire +2 more sources
Leukemia Stem Cells in Chronic Myeloid Leukemia
2019Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder characterized by a chromosome translocation that generates the BCR-ABL oncogene encoding a constitutively activated tyrosine kinase. Although BCR-ABL tyrosine kinase inhibitors (TKIs) are highly effective in treating CML at chronic phase, a number of patients develop drug resistance
Yi, Shan +3 more
openaire +2 more sources
Chronic myeloid leukemia and chronic lymphocytic leukemia
Journal of the American Academy of Physician Assistants, 2014openaire +2 more sources